Outlook

## IRAS 1011239. Amendment

**From** no-reply-IRAS <no-reply-iras@hra.nhs.uk>
**Date** Thu 16/04/2026 14:44
**To** salma2.begum@qmul.ac.uk <salma2.begum@qmul.ac.uk>

IRAS project ID: 1011239
Sponsor amendment reference: Non substantial amendment 2
Sponsor amendment date: 10/04/2026

Thank you for submitting your amendment. You have submitted this as a Non-Substantial, No Study-Wide Review Required amendment. In accordance with the outcome of your completed amendment tool, this amendment requires no further regulatory review. Please now share this amendment with your UK research sites, in accordance with the instructions in your completed amendment tool.

For studies with more than one UK research site, your amendment will now be automatically shared with the R&D offices of any NHS/HSC research sites in Scotland and Northern Ireland, but you should share the amendment by email directly with those Research team/s.

For all NHS research sites in England and Wales, please now share this amendment by email directly with those sites, including both the R&D offices and research teams.

Do not reply to this email as this is an unmonitored address and replies to this email cannot be responded to or read.

Best regards

**Health Research Authority**

2 Redman Place | Stratford | London | E20 1JQ
E. amendments@hra.nhs.uk
W.www.hra.nhs.uk

Sign up to receive our newsletter HRA Now.

This message may contain confidential information. If you are not the intended recipient please inform the sender that you have received the message in error before deleting it. Please do not disclose, copy or distribute information in this e-mail or take any action in relation to its contents. To do so is strictly prohibited and may be unlawful. Thank you for your co-operation..